SCHEMBL4864147

SCHEMBL4864147

CC(c1ccccc1)n1c(-c2cnn(-c3ccccc3)c2)c([N+](=O)[O-])c(=O)n(C2CCC2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.41
MTOR P42345 1/20 0.36
KDM5B Q9UGL1 2/20 0.35
DCTPP1 Q9H773 1/20 0.35
GRM1 Q13255 1/20 0.34
CREBBP Q92793 2/20 0.34
ADORA2A P29274 2/20 0.34
BRD4 O60885 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
KDM5A P29375 2/20 0.33
SLC6A2 P23975 3/20 0.33
PDE9A O76083 2/20 0.32
ALDH1A1 P00352 1/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
OPRM1 P35372 1/20 0.32
ROCK2 O75116 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867651 0.90 CREBBP (0.37) DCTPP1CREBBPBRD4SLC6A2PDE9A
SCHEMBL4858967 0.87 HSP90AA1 (0.44) HSP90AA1MTORGRM1CREBBPADORA2A
SCHEMBL4859896 0.86 HSP90AA1 (0.47) HSP90AA1KDM5BDCTPP1CREBBPADORA2A
SCHEMBL4792628 0.84 NPC1 (0.35) HSP90AA1MTORDCTPP1GRM1ADORA2A
SCHEMBL4792631 0.84 NPC1 (0.35) HSP90AA1MTORDCTPP1GRM1ADORA2A
SCHEMBL4867808 0.82 ADORA2B (0.39) DCTPP1CREBBPADORA2AADORA2BADORA1
SCHEMBL4891718 0.80 ADORA2B (0.41) ADORA2AADORA2BADORA1ALDH1A1
SCHEMBL4864154 0.80 HSP90AA1 (0.38) HSP90AA1MTORGRM1CREBBPADORA2A
SCHEMBL4771398 0.79 ADORA2A (0.38) HSP90AA1MTORKDM5BCREBBPADORA2A
SCHEMBL4769060 0.79 DCTPP1 (0.42) DCTPP1SLC6A2ALDH1A1CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 HSP90AA1 1863/4885MTOR 2711/4885KDM5B 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.